Dolby Laboratories Inc SEC Filings

Dolby Laboratories, Inc. reported that it has released its financial results for the fiscal quarter and fiscal year ended September 26, 2025, via a press release that is incorporated by reference as Exhibit 99.1. The company also declared a cash dividend of $0.36 per share on its Class A and Class B common stock, payable on December 10, 2025, to stockholders of record as of the close of business on December 2, 2025. Dolby noted that it regularly shares information with the public through its main website, investor relations site, SEC filings, press releases, conference calls, and webcasts.

Dolby Laboratories approved its 2026 Dolby Executive Bonus Plan for selected officers. The plan sets a target bonus of 100% of base salary for CEO Kevin Yeaman and 65% of base salary for each other named executive officer. Eligibility is limited to executives chosen by the Compensation Committee.

Actual payouts will be determined by target amounts adjusted for performance against non-GAAP operating income, revenue and/or other metrics, as assessed by the Committee. The Committee retains discretion to adjust awards, and the CEO may recommend increases or decreases of up to 25% for other executives. Plan funding is capped at 150% of target, and no payment may exceed the limitations in the company’s 2020 Stock Plan.

Dolby Laboratories (DLB) filed a Form 4 for CFO Robert Park. The filing reports 3,552 shares of Class A common stock withheld at $69.11 to cover taxes upon RSU vesting, a transaction exempt under Rule 16b‑3.

Following the withholding, Park beneficially owns 66,085 shares, including 38,186 shares underlying RSUs that remain subject to forfeiture until they vest. Holdings also include 350 shares acquired under the Employee Stock Purchase Plan on May 15, 2025.

Dolby Laboratories (DLB) reported insider activity by President & CEO and Director Kevin Yeaman. On 10/14/2025, he exercised an employee stock option for 25,000 Class A shares at $45.5 per share (code M), then sold 11,214 shares at a weighted average price of $68.5057 and 13,786 shares at a weighted average price of $69.173 (both code S), all held indirectly by a family trust. Following the reported transactions, 114,725 shares were beneficially owned indirectly by the trust. Holdings also include 127,735 RSUs that are subject to vesting.

Kevin J. Yeaman, President and CEO and a director of Dolby Laboratories (DLB), reported option exercise and related stock sale on 09/16/2025. He exercised an employee stock option with a $45.50 exercise price to acquire 25,000 shares of Class A common stock and immediately reported a sale of 25,000 Class A shares at a weighted average price of $71.6596. After these transactions he beneficially owned 139,725 shares indirectly through the Kevin and Rachel Yeaman Family Trust, including 127,735 Class A shares underlying restricted stock units that remain subject to forfeiture until they vest. The Form 4 was signed by an attorney-in-fact on 09/18/2025.

Form 144 filed for Dolby Laboratories, Inc. (DLB) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $1,791,487.50 and an approximate sale date of 09/16/2025. The filing states the shares were acquired on 09/16/2025 via stock option exercise from the issuer and paid for in cash. The filer or related parties sold multiple blocks of common stock in the prior three months: 25,000 on 08/12/2025 for $1,807,827.50, 2,491 on 07/16/2025 for $186,825.00, 39,875 on 07/15/2025 for $2,983,287.84, and 25,000 on 06/24/2025 for $1,850,530.00. The form includes the standard representation that the seller is not in possession of undisclosed material adverse information.

Dolby Laboratories director and SVP of Advanced Technology Group, Shriram Revankar, reported an insider sale of 7,000 shares of Class A common stock on 08/22/2025 at a reported price of $74.92 per share. After the sale, Revankar beneficially owned 70,435 shares. The filing discloses that 47,766 of those shares are Class A shares underlying restricted stock units that remain subject to forfeiture until they vest. The Form 4 was signed by an attorney-in-fact on 08/26/2025.

Form 144 filed for Dolby Laboratories (DLB): The filer notifies a proposed sale of 7,000 shares of Common Stock through Morgan Stanley Smith Barney on the NYSE with an approximate aggregate market value of $524,440, and an approximate sale date of 08/22/2025. The shares were acquired as restricted stock: 5,670 shares on 05/16/2023 and 1,330 shares on 12/15/2023. The filing reports no securities sold in the past three months by the selling person. The filer also signs the standard representation that they are not aware of any material nonpublic information about the issuer.

Kevin J. Yeaman, President and CEO and director of Dolby Laboratories (DLB), reported option exercise and an immediate sale of shares on 08/12/2025. He exercised an employee stock option to acquire 25,000 shares of Class A common stock at an exercise price of $45.50 per share and simultaneously sold 25,000 shares at a weighted-average sale price of $72.3131 per share. Following these transactions, the reporting person beneficially owns 139,725 shares of Class A common stock indirectly through the Kevin and Rachel Yeaman Family Trust; this total includes 127,735 shares underlying restricted stock units that remain subject to forfeiture until they vest. The filing also notes the exercised option was part of a larger grant covering 194,399 shares, and the sold shares were transacted in multiple sales at prices ranging from $71.63 to $72.59.